Interleukin-2-receptor blockade with daclizumab decreases the incidence of acute rejection in pediatric lung transplant recipients.
Sweet
S C.
SC
Washington University School of Medicine, St. Louis, Mo, USA
De La Morena
M T.
MT
Shapiro
S D.
SD
Mendeloff
E N.
EN
Huddleston
C B.
CB